Objective
Whether endoscopic surveillance would improve the outcomes of esophageal adenocarcinoma in patients previously diagnosed with Barrett's esophagus remains unclear. This meta‐analysis aimed to assess the survival advantages of endoscopic surveillance for patients with Barrett's esophagus.
Methods
Databases including PubMed, the Web of Science, and the Cochrane Library were examined systematically from their inception to July 2017, for articles related to the survival outcomes of esophageal adenocarcinoma in patients with Barrett's esophagus under endoscopic surveillance. Adjusted hazard estimates were adopted to determine overall results with 95% confidence intervals (CIs), using the fixed‐effect model. We conducted subgroup and sensitivity analyses using the “metan” command in Stata software to assess the stability of the overall results. Begg's test, Egger's test and the funnel plot were used to evaluate the presence of publication bias.
Results
A total of eight studies (two case‐control and six cohort studies) were finally included in our current study. Compared with patients with esophageal adenocarcinoma that was not detected by surveillance, a significant 29% reduction in mortality from esophageal adenocarcinoma was observed among patients under endoscopic surveillance (adjusted hazard ratio [HR] 0.71, 95% CI 0.66–0.77). This effect was presented in both the USA (adjusted HR 0.71, 95% CI 0.65–0.78) and Europe (adjusted HR 0.71, 95% CI 0.60–0.83). We found no evidence of publication bias.
Conclusions
Our meta‐analysis supports the concept that endoscopic surveillance for patients with Barrett's esophagus could improve the prognosis of esophageal adenocarcinoma. More well‐designed prospective studies are needed to confirm this association.